Displaying 61 - 80 of 132
Leon Max, Inc., also d/b/a Max Studio
Sears, Roebuck and Co.; Kmart Corporation; and Kmart.com, LLC, United States of America (for the Federal Trade Commission)
Boehringer Ingelheim Pharmaceuticals, Inc.
Mallett, Christopher, also d/b/a Department of Consumer Services Protection Commission, U.S. Debt Care, et al.
Mylan Pharmaceuticals Inc. v. Sebelius
Graco, Inc., Illinois Tool Works Inc., and ITW Finishing LL
Roberts, Brian L.
On 12/16/2011, Brian L. Roberts, the Chief Executive Officer of Comcast Corporation, agreed to pay a $500,000 penalty to settle Federal Trade Commission charges that he violated the Hart-Scott-Rodino Antitrust Improvement Act (HSR Act) in connection with his acquisitions of Comcast stock between 2007 and 2009. The FTC alleged that Roberts failed to file required notices before acquiring Comcast shares. The amount of the fine was limited by a number of factors, including that the violation was inadvertent and technical; that it was apparently due to faulty advice from outside counsel; that Roberts did not gain financially from the violation; and that he reported the violation promptly once it was discovered.
Making Home Affordable Program, et al.
Church & Dwight Co., Inc.
Bisaro, Paul
Federal Housing Modification Department, Inc., also d/b/a Nations Housing Modification Center and Loan Modification Reform Association, et al.
Promedica Health System, Inc.
Liberty Media Corporation and John C. Malone, United States of America (for the Federal Trade Commission)
John C. Malone, CEO and Chairman of Discovery Holding Company, agreed to pay a $1.4 million civil penalty to settle Federal Trade Commission charges that he violated the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act) in connection with acquisitions of Discovery shares in 2005 and 2008. The FTC alleged that Malone failed to file the required notice in 2005 after buying Discovery shares, and then in 2008 purchased additional Discovery shares before the expiration of a waiting period required by the HSR Act.
CSL Limited, a corporation, and Cerberus-Plasma Holdings, LLC, In the Matter of
The FTC authorized a lawsuit to block CSL Limited’s proposed $3.1 billion acquisition of Talecris Biotherapeutics Holdings Corporation, charging that the deal would would substantially reduce competition in the U.S. markets for four plasma-derivative protein therapies – Immune globulin (Ig), Albumin, Rho-D, and Alpha-1. These therapies are used to treat patients suffering from illnesses such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, alpha-1 antitrypsin disease, and hemolytic disease of the newborn. In approving the administrative complaint seeking to block the deal, the Commission also authorized the staff to seek a preliminary injunction in federal district court in Washington, D.C., to stop the transaction pending completion of the administrative trial. Following the FTC's lawsuit to block the transaction, CSL Limited announced that it would not proceed with its proposed acquisition.
Displaying 61 - 80 of 132